“…This population corresponded to 28 % of our global population, underlining the potential positive evolution of the prognosis for MSCC patients. Recent reports have suggested a potential improvement in this prognosis, mainly for patients with lung or renal cancer [5], and such improvements could be explained by the refinement of surgical techniques, and by the improvement in the use of systemic therapy for these two tumor types [13,14]. In our series, breast cancer and hematological primaries, both known to display a high sensitivity to systemic treatments, represented more than 80 % of the long-term survival patients.…”